AP
INSY

AHL Partners’s Insys Therapeutics, Inc. INSY Stock Holding History

AHL Partners’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-15,622
Closed -$139K – 1424
2017
Q3 		$139K Buy
+15,622
New +$161K ﹤0.01% 1215
2016
Q4 		– Sell
-15,543
Closed -$183K – 1261
2016
Q3 		$183K Sell
15,543
-6,601
-30% -$100K 0.01% 1097
2016
Q2 		$286K Buy
+22,144
New +$323K 0.02% 719
2016
Q1 		– Sell
-78,444
Closed -$2.25M – 866
2015
Q4 		$2.25M Buy
78,444
+64,435
+460% +$1.79M 0.17% 222
2015
Q3 		$399K Sell
14,009
-95,355
-87% -$3.51M 0.06% 464
2015
Q2 		$3.93M Sell
109,364
-3,326
-3% -$104K 0.16% 294
2015
Q1 		$3.27M Buy
+112,690
New +$2.98M 0.13% 363

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AHL Partners's INSY Position: Q4 2017 in Review

AHL Partners sold out of Insys Therapeutics, Inc. (INSY) in Q4 2017, closing a stake of 15,622 shares — an estimated $139K sold.

AHL Partners first reported a position in INSY in Q1 2015 and held it in 7 quarters. The position peaked at $3.93M in Q2 2015. 112 funds tracked by Wall St. Rank hold INSY as of Q4 2017.

  • AHL Partners reported no remaining Insys Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • AHL Partners sold 15,622 Insys Therapeutics, Inc. shares in Q4 2017, an estimated $139K.
  • AHL Partners first reported a position in Insys Therapeutics, Inc. in Q1 2015 and held it in 7 quarters.
  • AHL Partners's Insys Therapeutics, Inc. position peaked at $3.93M in Q2 2015.
  • 112 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.